Genetic testing for warfarin dosing? Not yet ready for prime time

被引：27

作者：

Bussey, Henry I. ^{[1
]}

Wittkowsky, Ann K. ^{[2
]}

Hylek, Elaine M. ^{[3
]}

Walker, Marie B.

机构：

[1] Univ Texas Austin, Coll Pharm, Austin, TX USA

[2] Univ Washington, Sch Pharm, Seattle, WA 98195 USA

[3] Boston Univ, Sch Med, Boston, MA 02215 USA

来源：

PHARMACOTHERAPY | 2008年 / 28卷 / 02期

关键词：

D O I：

10.1592/phco.28.2.141

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：141 / 143

页数：3

共 13 条

[1] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].

Aquilante, CL ;

Langaee, TY ;

Lopez, LM ;

Yarandi, HN ;

Tromberg, JS ;

Mohuczy, D ;

Gaston, KL ;

Waddell, CD ;

Chirico, MJ ;

Johnson, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302

[2] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin [J].

Gage, BF ;

Eby, C ;

Milligan, PE ;

Banet, GA ;

Duncan, JR ;

McLeod, HL .

THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :87-94

[3] Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data [J].

Hillman, Michael A. ;

Wilke, Russell A. ;

Yale, Steven H. ;

Vidaillet, Humberto J. ;

Caldwell, Michael D. ;

Glurich, Ingrid ;

Berg, Richard L. ;

Schmelzer, John ;

Burmester, James K. .

CLINICAL MEDICINE & RESEARCH, 2005, 3 (03) :137-145

[4]

JOHNSON L, 2007, WASHINGTON POST 0112

[5]

McWilliam A., 2006, HLTH CARE SAVINGS PE

[6] Genetic-based dosing in orthopedic patients beginning warfarin therapy [J].

Millican, Eric A. ;

Lenzini, Petra A. ;

Milligan, Paul E. ;

Grosso, Leonard ;

Eby, Charles ;

Deych, Elena ;

Grice, Gloria ;

Clohisy, John C. ;

Barrack, Robert L. ;

Burnett, R. Stephen J. ;

Voora, Deepak ;

Gatchel, Susan ;

Tiemeier, Amy ;

Gage, Brian F. .

BLOOD, 2007, 110 (05) :1511-1515

[7]

PALCA J, 2005, GENOME PROJECT BEGIN

[8] The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen [J].

Sconce, EA ;

Khan, TI ;

Wynne, HA ;

Avery, P ;

Monkhouse, L ;

King, BP ;

Wood, P ;

Kesteven, P ;

Daly, AK ;

Kamali, F .

BLOOD, 2005, 106 (07) :2329-2333

[9]

*US FDA, CRITICAL PATH INITIA

[10] Prospective dosing of warfarin based on cytochrome P-4502C9 genotype [J].

Voora, D ;

Eby, C ;

Linder, MW ;

Milligan, PE ;

Bukaveckas, BL ;

McLeod, HL ;

Maloney, W ;

Clohisy, J ;

Burnett, RS ;

Grosso, L ;

Gatchel, SK ;

Gage, BF .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) :700-705

← 1 2 →